Previous 10 | Next 10 |
Gainers: [[AAME]] +31.5%. [[MRKR]] +28.3%. [[KNSA]] +13.8%. [[WKEY]] +11.8%. [[SRPT]] +7.6%.Losers: [[PROG]] -6%. [[UPST]] -5.8%. [[ALPN]] -5.8%. [[SYBX]] -4.7%. [[ROAD]] -4.4%. For further details see: SRPT, UPST, MRKR and ALPN among after-hours movers
Marker Therapeutics, Inc. Announces Closing of Public Offering of Common Stock PR Newswire HOUSTON , March 16, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-gen...
Gainers: NLS Pharmaceutics (NLSP) +87%.Entera Bio (ENTX) +72%.Seelos Therapeutics (SEEL) +69%.Ebang International (EBON) +43%.Perpetua Resources (PPTA) +27%.AMREP (AXR) +21%.22nd Century (XXII) +19%.Aemetis (AMTX) +18%.LendingClub (LC) +18%.MicroVision (MVIS) +17%.Losers: Marker The...
Marker Therapeutics (MRKR) announces the pricing of an underwritten public offering of 28.57M shares at a public offering price of $1.75/share with expected gross proceeds of about $50M.Company has granted the underwriters a 30-day option to purchase up to an additional 4.29M shares. Offering...
Marker Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock PR Newswire HOUSTON , March 12, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generati...
Marker Therapeutics (MRKR) slumped 23.3% in after hours trade on commencing an underwritten public offering of shares; underwriters granted 30-day option to purchase additional shares.Offer size, terms not yet disclosed. For further details see: Marker Therapeutics under ...
Marker Therapeutics, Inc. Announces Proposed Public Offering of Common Stock PR Newswire HOUSTON , March 11, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company specializing in the development of next-gener...
Marker Therapeutics (MRKR): FY GAAP EPS of -$0.61 misses by $0.02.Revenue of $0.47M (+123.8% Y/Y) misses by $0.01M.Press Release For further details see: Marker Therapeutics EPS misses by $0.02, misses on revenue
Marker Therapeutics Reports Fiscal Year 2020 Operating and Financial Results - Dosed first patient in the Company's Phase 2 trial of MT-401, its lead MultiTAA-specific T cell product candidate, for the treatment of post-transplant acute myeloid leukemia - - Completed constru...
Marker Therapeutics Announces Dosing of First Patient in Phase 2 Trial of MT-401 in Acute Myeloid Leukemia Following Stem Cell Transplant Topline readout of active disease group in AML trial expected in Q1 2022 PR Newswire HOUSTON , March 3, 2021 /PRNewswire/...
News, Short Squeeze, Breakout and More Instantly...
Marker Therapeutics Inc. Company Name:
MRKR Stock Symbol:
NASDAQ Market:
Marker Therapeutics Inc. Website:
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who relapsed within 90 days of anti-CD19 CAR T cell therapy remains in complete response...
Preliminary data from study in patients with lymphoma enrolled at City of Hope National Medical Center was presented at the 11 th Global Summit on Hematologic Malignancies in Whistler, BC, Canada Study participants tolerated initial dose level well and demonstrated durab...